Angus A Wilfong

Texas Children's Hospital, Houston, Texas, United States

Are you Angus A Wilfong?

Claim your profile

Publications (34)152.89 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The underlying genetic etiology of rhabdomyolysis remains elusive in a significant fraction of individuals presenting with recurrent metabolic crises and muscle weakness. Using exome sequencing, we identified bi-allelic mutations in TANGO2 encoding transport and Golgi organization 2 homolog (Drosophila) in 12 subjects with episodic rhabdomyolysis, hypoglycemia, hyperammonemia, and susceptibility to life-threatening cardiac tachyarrhythmias. A recurrent homozygous c.460G>A (p.Gly154Arg) mutation was found in four unrelated individuals of Hispanic/Latino origin, and a homozygous ∼34 kb deletion affecting exons 3-9 was observed in two families of European ancestry. One individual of mixed Hispanic/European descent was found to be compound heterozygous for c.460G>A (p.Gly154Arg) and the deletion of exons 3-9. Additionally, a homozygous exons 4-6 deletion was identified in a consanguineous Middle Eastern Arab family. No homozygotes have been reported for these changes in control databases. Fibroblasts derived from a subject with the recurrent c.460G>A (p.Gly154Arg) mutation showed evidence of increased endoplasmic reticulum stress and a reduction in Golgi volume density in comparison to control. Our results show that the c.460G>A (p.Gly154Arg) mutation and the exons 3-9 heterozygous deletion in TANGO2 are recurrent pathogenic alleles present in the Latino/Hispanic and European populations, respectively, causing considerable morbidity in the homozygotes in these populations.
    No preview · Article · Jan 2016 · The American Journal of Human Genetics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish whether addition of cannabidiol to existing anti-epileptic regimens would be safe, tolerated, and efficacious in children and young adults with treatment-resistant epilepsy. Methods: In this open-label trial, patients (aged 1-30 years) with severe, intractable, childhood-onset, treatment-resistant epilepsy, who were receiving stable doses of antiepileptic drugs before study entry, were enrolled in an expanded-access programme at 11 epilepsy centres across the USA. Patients were given oral cannabidiol at 2-5 mg/kg per day, up-titrated until intolerance or to a maximum dose of 25 mg/kg or 50 mg/kg per day (dependent on study site). The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percentage change in the mean monthly frequency of motor seizures at 12 weeks. The efficacy analysis was by modified intention to treat. Comparisons of the percentage change in frequency of motor seizures were done with a Mann-Whitney U test. Results: Between Jan 15, 2014, and Jan 15, 2015, 214 patients were enrolled; 162 (76%) patients who had at least 12 weeks of follow-up after the first dose of cannabidiol were included in the safety and tolerability analysis, and 137 (64%) patients were included in the efficacy analysis. In the safety group, 33 (20%) patients had Dravet syndrome and 31 (19%) patients had Lennox-Gastaut syndrome. The remaining patients had intractable epilepsies of different causes and type. Adverse events were reported in 128 (79%) of the 162 patients within the safety group. Adverse events reported in more than 10% of patients were somnolence (n=41 [25%]), decreased appetite (n=31 [19%]), diarrhoea (n=31 [19%]), fatigue (n=21 [13%]), and convulsion (n=18 [11%]). Five (3%) patients discontinued treatment because of an adverse event. Serious adverse events were reported in 48 (30%) patients, including one death-a sudden unexpected death in epilepsy regarded as unrelated to study drug. 20 (12%) patients had severe adverse events possibly related to cannabidiol use, the most common of which was status epilepticus (n=9 [6%]). The median monthly frequency of motor seizures was 30·0 (IQR 11·0-96·0) at baseline and 15·8 (5·6-57·6) over the 12 week treatment period. The median reduction in monthly motor seizures was 36·5% (IQR 0-64·7). Interpretation: Our findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy. Randomised controlled trials are warranted to characterise the safety profile and true efficacy of this compound. Funding: GW Pharmaceuticals, Epilepsy Therapy Project of the Epilepsy Foundation, Finding A Cure for Epilepsy and Seizures.
    Full-text · Article · Dec 2015 · The Lancet Neurology
  • Mindl M Messinger · Brady S Moffett · Angus Wilfong
    [Show abstract] [Hide abstract]
    ABSTRACT: Materials and methods: Obesity has been shown to affect the disposition of water soluble medications in pediatric patients. There are no published data describing serum phenytoin concentrations in obese pediatric patients. A retrospective descriptive study was designed that included patients from 2011-2013 between 2-19 years of age who received a dose of fosphenytoin with a subsequent serum phenytoin concentration, drawn 2-4 hours post-loading dose. Body mass index (BMI) was calculated and patients were categorized by BMI percentiles into underweight (<5 percentile), normal weight (5-84 percentile), overweight (85-94 percentile), and obese (>=95 percentile). Descriptive statistical analysis and comparisons between groups occurred to determine differences in serum phenytoin concentrations. Multivariable linear regression analysis was performed to determine the affect of body habitus on serum phenytoin concentrations. Results: 110 patients met study criteria (male 51.8%, mean age 8.3+4.9 years). Patients were normal weight (47.3%), underweight (20.9%), over weight (14.6%), and obese (17.3%). No significant differences were identified between groups in regards to patient demographics, with the exception of weight (p<0.05). The mean fosphenytoin dose was 23.4+5.7 mg PE/kg and the serum phenytoin concentration was 22.4+6.8 mg/L measured at 2.9+0.6 hours post-dose, and this did not vary significantly across groups (p>0.05). Multivariable linear regression identified body habitus as a non-significant predictor of serum phenytoin concentrations (p>0.05). Patients of higher BMI did not require further antiepileptic therapy as compared to patients with lower BMI (p>0.05). Discussion: Contrary to the adult population, loading dose adjustments do not appear to be required in pediatric patients. Conclusion: Obesity does not affect serum phenytoin concentrations in pediatric patients after intravenous bolus fosphenytoin administration.
    No preview · Article · Sep 2015 · Therapeutic drug monitoring
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuropathology of resected brain tissue has revealed an association of focal cortical dysplasia (FCD) with drug-resistant epilepsy (DRE). Recent studies have shown that the mechanistic target of rapamycin (mTOR) pathway is hyperactivated in FCD as evidenced by increased phosphorylation of the ribosomal protein S6 (S6) at serine 240/244 (S240/244), a downstream target of mTOR. Moreover, extracellular regulated kinase (ERK) has been shown to phosphorylate S6 at serine 235/236 (S235/236) and tuberous sclerosis complex 2 (TSC2) at serine 664 (S664) leading to hyperactive mTOR signaling. We evaluated ERK phosphorylation of S6 and TSC2 in two types of FCD (FCD I and FCD II) as a candidate mechanism contributing to mTOR pathway dysregulation. Tissue samples from patients with tuberous sclerosis (TS) served as a positive control. Immunostaining for phospho-S6 (pS6240/244 and pS6235/236), phospho-ERK (pERK), and phospho-TSC2 (pTSC2) was performed on resected brain tissue with FCD and TS. We found increased pS6240/244 and pS6235/236 staining in FCD I, FCD II and TS compared to normal-appearing tissue, while pERK and pTSC2 staining was increased only in FCD IIb and TS tissue. Our results suggest that both the ERK and mTOR pathways are dysregulated in FCD and TS; however, the signaling alterations are different for FCD I as compared to FCD II and TS.
    No preview · Article · Sep 2015 · Neuropathology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intracarotid amobarbital procedure (IAP) is acknowledged as the gold standard test for language lateralization. EEG is performed routinely during IAP to monitor the anesthetization of a brain hemisphere. Here, we studied the correlation between the early EEG changes using envelope trend and the clinical outcome of IAP. Fifty consecutive patients underwent IAP at Texas Children's Hospital (2004-2009). Intracarotid amobarbital procedure was considered "complete" or "incomplete" based on the outcome if the procedure was completed or aborted due to behavior changes. Envelope trend was used to calculate the median EEG amplitude changes within the first 60s of IAP. Statistical analysis was performed to determine the role of EEG changes and clinical features on the procedure outcome. Only 30 IAP-EEG files were available for review. Amobarbital was administered at the dose of 60-150mg (mean: 110±20). The intracarotid amobarbital procedure was recorded as complete in 23 patients and incomplete in 7 patients. EEG changes occurred within the first few seconds following amobarbital injection. Following amobarbital injection, focal slowing was present in the ipsilateral frontal region or both ipsilateral and contralateral frontal regions. Elapsed time to the first EEG change or duration and change in median EEG amplitude in the ipsilateral frontal regions were indifferent between the complete and incomplete groups (p>0.05). However, the median amplitude changes between the ipsilateral and contralateral frontal regions within each group were found significant only in the complete group (p<0.05), suggesting ipsilateral without contralateral frontal slowing. Other than age at the time of IAP (p=0.03), none of the other clinical features correlated with the clinical outcome of IAP (p>0.05). Early EEG changes during IAP using envelope trend may predict successful completion of the IAP test. Younger children are at risk of behavioral changes during IAP. Copyright © 2014 Elsevier Inc. All rights reserved.
    No preview · Article · Jan 2015 · Epilepsy & Behavior
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 5q31.3 microdeletion syndrome is characterized by neonatal hypotonia, encephalopathy with or without epilepsy, and severe developmental delay, and the minimal critical deletion interval harbors three genes. We describe 11 individuals with clinical features of 5q31.3 microdeletion syndrome and de novo mutations in PURA, encoding transcriptional activator protein Pur-α, within the critical region. These data implicate causative PURA mutations responsible for the severe neurological phenotypes observed in this syndrome.
    Full-text · Article · Oct 2014 · The American Journal of Human Genetics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resting-state functional MRI (rs-fMRI) identifies resting-state networks (RSN) in the human brain by analyzing the connectivity of anatomically remote neuronal populations with synchronous low-frequency fluctuation in blood oxygen level-dependent (BOLD) signal. Network analysis has informed the understanding of functional brain organization and is beginning to reveal the impact that neurological disorders such as epilepsy may have on the developing cerebral cortex. Among children undergoing epilepsy surgery, mapping the brain networks supporting language, sensorimotor and visual function is a critical part of the preoperative evaluation. However, task-based functional mapping techniques are particularly difficult in immature patients and those with severe impairment. Functional mapping of RSN is a promising tool that may help circumvent the challenges of adequate cooperation and limited abilities of developmentally disabled children to perform age-appropriate functions. We discuss the current methodology of rs-fMRI in the pediatric population, review the literature of rs-fMRI in pediatric epilepsy and present our experience of using rs-fMRI for functional network mapping in children undergoing epilepsy surgery. © 2014 S. Karger AG, Basel.
    No preview · Article · Sep 2014 · Pediatric Neurosurgery
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic laser amygdalohippocampotomy (SLAH) is a minimally-invasive potential alternative to open resection for mesial temporal lobe epilepsy (MTLE), but outcome data are limited (Willie et al, 2014). Here we present data on effectiveness, safety, and related findings collected from investigator-initiated, prospective, observational studies at 7 centers.
    Full-text · Article · Aug 2014 · Neurosurgery
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genomic copy-number variations (CNVs) constitute an important cause of epilepsies and other human neurological disorders. Recent advancement of technologies integrating genome-wide CNV mapping and sequencing is rapidly expanding the molecular field of pediatric neurodevelopmental disorders. In a previous study, a novel epilepsy locus was identified on 6q16.3q22.31 by linkage analysis in a large pedigree. Subsequent array comparative genomic hybridization (array CGH) analysis of four unrelated cases narrowed this region to ∼5 Mb on 6q22.1q22.31. We sought to further narrow the critical region on chromosome 6q22. Array CGH analysis was used in genome-wide screen for CNVs of a large cohort of patients with neurological abnormalities. Long-range PCR and DNA sequencing were applied to precisely map chromosomal deletion breakpoints. Finally, real-time qPCR was used to estimate relative expression in the brain of the candidate genes. We identified six unrelated patients with overlapping microdeletions within 6q22.1q22.31 region, three of whom manifested seizures. Deletions were found to be de novo in 5/6 cases, including all subjects presenting with seizures. We sequenced the deletion breakpoints in four patients and narrowed the critical region to a ∼250-kb segment at 6q22.1 that includes NUS1, several expressed sequence tags (ESTs) that are highly expressed in the brain, and putative regulatory sequences of SLC35F1. Our findings indicate that dosage alteration in particular, of NUS1, EST AI858607, or SLC35F1 are important contributors to the neurodevelopmental phenotype associated with 6q22 deletion, including epilepsy and tremors.European Journal of Human Genetics advance online publication, 14 May 2014; doi:10.1038/ejhg.2014.75.
    Full-text · Article · May 2014 · European journal of human genetics: EJHG
  • Angus A Wilfong · Daniel J Curry
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypothalamic hamartomas (HHs) present a difficult medical problem, manifested by gelastic seizures, which are often medically intractable. Although existing techniques offer modest surgical outcomes with the potential for significant morbidity, the relatively novel technique of magnetic resonance imaging (MRI)-guided stereotactic laser ablation (SLA) offers a potentially safer, minimally invasive method with high efficacy for the HH treatment. We report here on 14 patients with medically refractory gelastic epilepsy who underwent stereotactic frame-based placement of an MR-compatible laser catheter (1.6 mm diameter) through a 3.2-mm twist drill hole. A U.S. Food and Drug Administration (FDA)-cleared laser surgery system (Visualase, Inc.) was utilized to ablate the HH, using real-time MRI thermometry. Seizure freedom was obtained in 12 (86%) of 14 cases, with mean follow-up of 9 months. There were no permanent surgical complications, neurologic deficits, or neuroendocrine disturbances. One patient had a minor subarachnoid hemorrhage that was asymptomatic. Most patients were discharged home within 1 day. SLA was demonstrated to be a safe and effective minimally invasive tool in the ablation of epileptogenic HH. Because use of SLA for HH is being adopted by other medical centers, further data will be acquired to help treat this difficult disorder.
    No preview · Article · Dec 2013 · Epilepsia
  • Darcy Krueger · Angus Wilfong · David N Franz

    No preview · Article · Nov 2013 · Annals of Neurology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of TSC. We report the first prospective human clinical trial to directly assess whether everolimus will also benefit epilepsy in TSC patients. Methods: The effect of everolimus on seizure control was assessed using a prospective, multicenter, open-label, phase I/II clinical trial. Patients≥2 years of age with confirmed diagnosis of TSC and medically refractory epilepsy were treated for a total of 12 weeks. The primary endpoint was percentage of patients with a ≥50% reduction in seizure frequency over a 4-week period before and after treatment. Secondary endpoints assessed impact on electroencephalography (EEG), behavior, and quality of life. Results: Twenty-three patients were enrolled, and 20 patients were treated with everolimus. Seizure frequency was reduced by ≥50% in 12 of 20 subjects. Overall, seizures were reduced in 17 of the 20 by a median reduction of 73% (p<0.001). Seizure frequency was also reduced during 23-hour EEG monitoring (p=0.007). Significant reductions in seizure duration and improvement in parent-reported behavior and quality of life were also observed. There were 83 reported adverse events that were thought to be treatment-related, all of which were mild or moderate in severity. Interpretation: Seizure control improved in the majority of TSC patients with medically refractory epilepsy following treatment with everolimus. Everolimus demonstrated additional benefits on behavior and quality of life. Treatment was safe and well tolerated. Everolimus may be a therapeutic option for refractory epilepsy in this population.
    Full-text · Article · Nov 2013 · Annals of Neurology
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND:: Invasive monitoring using subdural electrodes is often valuable for characterizing the anatomic source of seizures in intractable epilepsy. Covering the interhemispheric surface with subdural electrodes represents a particular challenge, with potentially higher risk of complications than covering the dorsolateral cortex. OBJECTIVE:: To better understand the safety and utility of interhemispheric subdural electrodes (IHSE). METHODS:: We retrospectively reviewed the charts of twenty-four patients who underwent implantation of IHSE by a single neurosurgeon from 2003-2010. Generous midline exposure, meticulous preservation of veins, and sharp micro-dissection were employed to facilitate safe interhemispheric grid placement under direct visualization. RESULTS:: The number of IHSE contacts implanted ranged from 10-106 (mean=39.8) per patient. Monitoring lasted for 5.5 days on average (range 2-24 days), with an adequate sample of seizures captured in all patients prior to explantation, and with a low complication rate similar to that reported for grid implantation of the dorsolateral cortex. One patient (out of 24) experienced symptomatic mass effect. No other complications clearly related to grid implantation and monitoring, such as clinically evident neurological deficits, infection, hematoma or infarction, were noted. Among patients implanted with IHSE, monitoring led to a paramedian cortical resection in 67%, a resection in a region not covered by IHSE in 17%, and explantation without resection in 17%. CONCLUSION:: When clinical factors suggest the possibility of an epileptic focus at or near the midline, invasive monitoring of the paramedian cortex with interhemispheric grids can be safely used to define the epileptogenic zone and map local cortical function.
    No preview · Article · Apr 2013 · Neurosurgery
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Neurologic morbidity is increasingly recognized in survivors of surgery for congenital heart disease (CHD). Seizures after cardiac surgery are associated with increased risk of neurodevelopmental impairment. Recently, antiepileptic drug (AED) use has been identified as a risk factor associated with decreased survival in children after surgery for CHD. The purpose of our study was to describe trends and outcomes in AED use in children after surgery for CHD. Methods: Retrospective review using the Pediatric Health Information System database identified children (<18 years) who underwent a cardiac surgical procedure between January 1, 2001 and December 31, 2011. We excluded patients who underwent isolated arterial duct ligation and patients who were admininstered AED’s during the first 48 hours of admission. The first admission during the study period was used and subsequent admissions were excluded. Patients were divided by age groups from neonates to adolescents and hospitals were categorized according to mean annual caseload: low volume (<150 cases) and high volume (>150 cases). Patient demographics, length of hospital stay (LOS), in hospital mortality, RACHS-1 score, use of extracorporeal membrane oxygenation (ECMO) or ventricular assist device (VAD), use of procoagulant medications and use of AEDs were collected. Descriptive statistics were used to characterize the population. Student’s t-test, chi-squared analysis, and multivariate logistic regression were used to identify differences in patients who received AEDs to patients who did not receive and AED. A p-value < 0.05 was considered significant. Results: 53,209 patients were identified (54.5% male). Infants were the largest age category (n=21,869, 41.1%). Majority of patients were Caucasian (66.6%). Patients with Trisomy 21 accounted for 10.9% of the population and other genetic or chromosomal abnormalities were present in 7.0% of the population. Cardiac arrest or CPR occurred in 3% and a cerebrovascular accident was documented in 1.3%. Median RACHS-1 score was 3 with 86.2% undergoing surgery under cardiopulmonary bypass. ECMO was used in 3.4% and VAD in 0.33%. 83% of cardiac surgeries occurred in high volume hospitals. AEDs were used in 2,782 patients (5.23%). Phenobarbital was the most commonly administered AED (57.9%). Mortality (3% vs 19.6%, p<0.01) and LOS (7 vs 32 days, p<0.01) were higher in children receiving AEDs. High surgical volume hospitals had higher use of AED (5.3% vs 4.6%, p<0.01). On multivariate analysis significant risk factors for AED use included (adjusted odds ratio): young age (1.9), ECMO use (2.8), heart transplantation (1.7), genetic or chromosomal disorders (1.6), cerebrovascular accident (14.4), cardiac arrest (1.9). Conclusion: AED use was associated with increased mortality and LOS after surgery for CHD. AED use was associated with younger age at surgery, heart transplantation, genetic or chromosomal disorders, as well as cerebrovascular accident, cardiac arrest and the need for ECMO.
    No preview · Conference Paper · Oct 2012
  • Daniel J Curry · Ashok Gowda · Roger J McNichols · Angus A Wilfong
    [Show abstract] [Hide abstract]
    ABSTRACT: For about 30% of epilepsy patients, pharmaceutical therapy fails to control their seizures. MR-guided laser interstitial thermal therapy (MRgLITT) allows for real-time thermal monitoring of the ablation process and feedback control over the laser energy delivery. We report on minimally invasive surgical techniques of MRgLITT and short-term follow-up results from the first five pediatric cases in which this system was used to ablate focal epileptic lesions. We studied the patients with MRI of the brain, localized the seizure with video-EEG and used the Visualase Thermal Therapy 25 System for laser ablation of their seizure foci. All 5 patients are seizure free and there were no complications as of 2-13-month follow-up. MR-guided laser interstitial thermal therapy has a significant potential to be a minimally invasive alternative to more conventional techniques to surgically treat medically refractory epilepsy in children.
    No preview · Article · Jun 2012 · Epilepsy & Behavior
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have identified a rare small (~450 kb unique sequence) recurrent deletion in a previously linked attention-deficit hyperactivity disorder (ADHD) locus at 2q21.1 in five unrelated families with developmental delay (DD)/intellectual disability (ID), ADHD, epilepsy and other neurobehavioral abnormalities from 17 035 samples referred for clinical chromosomal microarray analysis. Additionally, a DECIPHER ( patient 2311 was found to have the same deletion and presented with aggressive behavior. The deletion was not found in either six control groups consisting of 13 999 healthy individuals or in the DGV database. We have also identified reciprocal duplications in five unrelated families with autism, developmental delay (DD), seizures and ADHD. This genomic region is flanked by large, complex low-copy repeats (LCRs) with directly oriented subunits of ~109 kb in size that have 97.7% DNA sequence identity. We sequenced the deletion breakpoints within the directly oriented paralogous subunits of the flanking LCR clusters, demonstrating non-allelic homologous recombination as a mechanism of formation. The rearranged segment harbors five genes: GPR148, FAM123C, ARHGEF4, FAM168B and PLEKHB2. Expression of ARHGEF4 (Rho guanine nucleotide exchange factor 4) is restricted to the brain and may regulate the actin cytoskeletal network, cell morphology and migration, and neuronal function. GPR148 encodes a G-protein-coupled receptor protein expressed in the brain and testes. We suggest that small rare recurrent deletion of 2q21.1 is pathogenic for DD/ID, ADHD, epilepsy and other neurobehavioral abnormalities and, because of its small size, low frequency and more severe phenotype might have been missed in other previous genome-wide screening studies using single-nucleotide polymorphism analyses.
    Full-text · Article · Apr 2012 · Human Molecular Genetics
  • J Lloyd Holder · Angus A Wilfong
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Epilepsy affects approximately 3 million people in the USA and up to 2% of the worldwide population. The yearly direct medical cost of epilepsy in the USA alone is estimated to be $9.5 billion. Epilepsy affects both children and adults and can significantly impair quality of life. Zonisamide is a second-generation antiepileptic drug (AED) that has broad-spectrum efficacy, a favorable side-effect profile and simpler dosing than earlier drugs. AREAS COVERED: The history of the development of zonisamide is reviewed in this paper. The data available demonstrating zonisamide's mechanism of action as a voltage-gated sodium channel inhibitor, a T-type calcium channel inhibitor, an enhancer of GABA release and an inhibitor of glutamate release are also reviewed. Four key Phase III clinical trials are reviewed in detail, as are subsequent postmarketing trials that have expanded the therapeutic indication for zonisamide. EXPERT OPINION: From the available clinical data, zonisamide is a viable first-line and adjunctive therapeutic for partial-onset epilepsy and should be considered as an adjunctive therapeutic for a wide-range of generalized epilepsies.
    No preview · Article · Oct 2011 · Expert Opinion on Pharmacotherapy
  • Ila S Reyes · David T Hsieh · Linda C Laux · Angus A Wilfong
    [Show abstract] [Hide abstract]
    ABSTRACT: Dravet syndrome is a rare epileptic encephalopathy linked to mutations in SCN1A (neuronal sodium channel α1 subunit) and characterized by an onset in infancy with polymorphous seizure types and developmental decline. It was reported recently that a proportion of patients previously diagnosed with alleged vaccine encephalopathy might possess SCN1A mutations and clinical histories that enabled a diagnosis of Dravet syndrome, but these results have not been replicated. We present here the cases of 5 children who presented for epilepsy care with presumed parental diagnoses of alleged vaccine encephalopathy caused by pertussis vaccinations in infancy. Their conditions were all rediagnosed years later, with the support of genetic testing, as Dravet syndrome. We hope that these cases will raise awareness of Dravet syndrome among health care providers who care for children and adolescents and aid in earlier recognition and diagnosis.
    No preview · Article · Aug 2011 · PEDIATRICS
  • Source
    Garima Agarwal · Angus A Wilfong · Joseph L Edmonds
    [Show abstract] [Hide abstract]
    ABSTRACT: Use of vagus nerve stimulation (VNS) has increased in the past decade, resulting in frequent revision cases for device failure. The authors report their series of children who underwent reimplantation of the VNS device after removal of old electrodes and leads. Patients with medically refractory seizures who underwent revision of VNS electrodes were included (n = 23). Twenty patients had high lead impedance and underwent removal of the device and replacement of the VNS electrodes during the same procedure. In 3 patients, electrodes and the device had been removed previously at an outside institution because of infection. None of the patients experienced any major complications. Mean operative time was 2.3 ± 0.9 hours. The reimplanted device worked well in all patients, and seizure control was similar to or better than that reported with the previous device. Thus, implantation of the VNS electrodes is reversible, and it appears that the electrodes can be removed or replaced safely if the device is not functioning properly.
    Full-text · Article · Jan 2011 · Otolaryngology Head and Neck Surgery
  • Jacob R Joseph · Rebecca J Schultz · Angus A Wilfong
    [Show abstract] [Hide abstract]
    ABSTRACT: This chart review investigated the efficacy and safety of rufinamide in 45 children and young adults who experienced a broad spectrum of partial and generalized seizure/epilepsy types which have been refractory to therapy. Of these patients, 19 (46%) achieved a >50% decrease in seizure frequency on rufinamide, and 7 patients achieved a >75% decrease in seizure frequency. While 17 (37.8%) patients stopped their trial of rufinamide prior to the end of the review period, only 2 (4.4%) were due to adverse effects. Although additional research must be done, this data shows promise that rufinamide is a safe and efficacious adjunct for cases of refractory epilepsy.
    No preview · Article · Jan 2011 · Epilepsy research

Publication Stats

497 Citations
152.89 Total Impact Points


  • 2005-2015
    • Texas Children's Hospital
      Houston, Texas, United States
  • 2003-2015
    • Baylor College of Medicine
      • • Department of Pediatrics
      • • Department of Molecular & Human Genetics
      Houston, Texas, United States
  • 2009
    • University of Pennsylvania
      • Department of Neurosurgery
      Philadelphia, PA, United States